# Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy

> **NCT00351871** · PHASE4 · COMPLETED · sponsor: **Louisiana State University Health Sciences Center in New Orleans** · enrollment: 400 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** PEG-Intron Plus REBETOL

## Key facts

- **NCT ID:** NCT00351871
- **Lead sponsor:** Louisiana State University Health Sciences Center in New Orleans
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2009-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00351871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00351871, "Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00351871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*